Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1996 1
1997 1
1999 1
2001 1
2002 2
2003 2
2004 3
2005 1
2010 2
2012 2
2013 1
2014 3
2016 1
2017 1
2018 1
2021 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Results by year
Filters applied: . Clear all
Page 1
Role of ribavirin in HCV treatment response: now and in the future.
Jain MK, Zoellner C. Jain MK, et al. Expert Opin Pharmacother. 2010 Mar;11(4):673-83. doi: 10.1517/14656560903580001. Expert Opin Pharmacother. 2010. PMID: 20163278 Review.
HCV genotype 1 infected patients require higher doses of ribavirin administered for a longer duration of time versus HCV genotypes 2 and 3 patients who respond effectively to Peg-IFN with lower doses of ribavirin and shorter duration of therapy. Higher serum concent …
HCV genotype 1 infected patients require higher doses of ribavirin administered for a longer duration of time versus HCV genotypes 2 …
Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.
Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Bodenheimer HC Jr, et al. Hepatology. 1997 Aug;26(2):473-7. doi: 10.1002/hep.510260231. Hepatology. 1997. PMID: 9252161 Clinical Trial.
We conducted a multicenter double-blind placebo-controlled trial of ribavirin 600 mg given orally twice daily for 36 weeks with follow-up off therapy for an additional 16 weeks. ...Adverse events were generally comparable between treatment groups except for a reversible …
We conducted a multicenter double-blind placebo-controlled trial of ribavirin 600 mg given orally twice daily for 36 weeks with follo …
Management of HCV-Related Liver Disease in Hemophilia and Thalassemia.
Rumi MG, Di Marco V, Colombo M. Rumi MG, et al. Semin Liver Dis. 2018 May;38(2):112-120. doi: 10.1055/s-0038-1655774. Epub 2018 Jun 5. Semin Liver Dis. 2018. PMID: 29871018 Free article. Review.
In patients with thalassemia, transfusion-related transmission of HCV was efficiently interrupted in 1992 with the advent of sensitive screening tests for testing donors for HCV, whereas treatment with interferon and ribavirin of infected thalassemics was constrained by an …
In patients with thalassemia, transfusion-related transmission of HCV was efficiently interrupted in 1992 with the advent of sensitive scree …
A pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infection.
Naik GS, Tyagi MG. Naik GS, et al. J Clin Exp Hepatol. 2012 Mar;2(1):42-54. doi: 10.1016/S0973-6883(12)60090-5. Epub 2012 Apr 12. J Clin Exp Hepatol. 2012. PMID: 25755405 Free PMC article. Review.
Despite the development of new anti-hepatitis C virus (HCV) drugs, ribavirin (RBV) remains the single most important drug to prevent relapse and is frequently included among newer regimens being developed with novel small molecule anti-HCV drugs. The current approved treat …
Despite the development of new anti-hepatitis C virus (HCV) drugs, ribavirin (RBV) remains the single most important drug to prevent …
Clinical Outcomes of Japanese Encephalitis after Combination Treatment of Immunoglobulin, Ribavirin, and Interferon-α2b.
Son H, Sunwoo JS, Lee SK, Chu K, Lee ST. Son H, et al. J Clin Neurol. 2021 Jul;17(3):428-434. doi: 10.3988/jcn.2021.17.3.428. J Clin Neurol. 2021. PMID: 34184451 Free PMC article.
We reviewed the medical records of the patients diagnosed with JE and treated either with supportive care only or with combination treatment of intravenous immunoglobulin, oral ribavirin, and subcutaneous interferon-alpha2b. RESULTS: Eleven patients were diagnosed w …
We reviewed the medical records of the patients diagnosed with JE and treated either with supportive care only or with combination treatment …
Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.
Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Takaki S, et al. J Gastroenterol. 2004 Jul;39(7):668-73. doi: 10.1007/s00535-003-1363-9. J Gastroenterol. 2004. PMID: 15293138
However, reversible hemolytic anemia is a common side effect of this therapy. METHODS: We determined those factors that contribute to ribavirin dose reduction due to anemia during this treatment by using multiple logistic regression analysis in Japanes …
However, reversible hemolytic anemia is a common side effect of this therapy. METHODS: We determined those factors that contri …
Prophylaxis for ribavirin-related anemia using eicosapentaenoic acid in chronic hepatitis C patients.
Suzuki M, Inage E, Minowa K, Saito N, Naritaka N, Tsubahara M, Ohtsuka Y, Tokita A, Shimizu T. Suzuki M, et al. Pediatr Int. 2012 Aug;54(4):528-31. doi: 10.1111/j.1442-200X.2012.03603.x. Epub 2012 Apr 19. Pediatr Int. 2012. PMID: 22375604 Clinical Trial.
The aim of this study was to evaluate the prophylactic effects of oral eicosapentaenoic acid (EPA) supplementation on ribavirin-induced hemolytic anemia in pediatric and young adult patients. ...However, one patient in the control group had a reduction …
The aim of this study was to evaluate the prophylactic effects of oral eicosapentaenoic acid (EPA) supplementation on ribavirin …
Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients.
Marcelin JR, Wilson JW, Razonable RR; Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Marcelin JR, et al. Transpl Infect Dis. 2014 Apr;16(2):242-50. doi: 10.1111/tid.12194. Epub 2014 Mar 13. Transpl Infect Dis. 2014. PMID: 24621016
RSV pneumonia developed in 24 patients. The median initial duration of oral ribavirin treatment was 10 days (range: 4-11); 4 patients were re-treated. Of 34 patients, 19 received a mean of 2.7 doses of IVIG. Two patients had adverse reactions to ribavirin ( …
RSV pneumonia developed in 24 patients. The median initial duration of oral ribavirin treatment was 10 days (range: 4-11); 4 p …
Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ, Perry CM. Scott LJ, et al. Drugs. 2002;62(3):507-56. doi: 10.2165/00003495-200262030-00009. Drugs. 2002. PMID: 11827565 Review.
Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-alpha-2b have been investigated. Combination therapy with subcutaneous interferon-alpha-2b [3 million units (MU) three times per week] plus oral …
Hence, alternative treatment strategies such as the addition of the broad spectrum antiviral agent ribavirin to interferon-alpha-2b h …
Synthesis and evaluation of a new phosphorylated ribavirin prodrug.
Dong SD, Lin CC, Schroeder M. Dong SD, et al. Antiviral Res. 2013 Jul;99(1):18-26. doi: 10.1016/j.antiviral.2013.04.014. Epub 2013 Apr 24. Antiviral Res. 2013. PMID: 23624267
Ribavirin is an important broad-spectrum antiviral drug. However, its utilization can be limited by its potential to cause hemolytic anemia as well as its variability in dosing levels and efficacy outcomes. To overcome these issues, we report on a new alkoxya …
Ribavirin is an important broad-spectrum antiviral drug. However, its utilization can be limited by its potential to cause hemolyt …
27 results